Sort
10,766 grants matching “checkpoint inhibitor”
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
$479,283Andre Elias Nel · University Of California Los Angeles · R01 · FY2024 · CA
Eukaryotic Chromosome Replication
$479,270Bonita J Brewer · University Of Washington · R01 · FY2008 · GM
Nanoscale Metal-Organic Frameworks Enable Radiotherapy-Radiodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Generate Tumor Vaccines and Potentiate Immunotherapy of Head and Neck Cancers
$479,142Wenbin Lin · University Of Chicago · R01 · FY2024 · CA
Targeting Autophagy in Hereditary Breast Cancer
$479,087Bing Xia · Rbhs -Cancer Institute Of New Jersey · R01 · FY2018 · CA
Tumor Organoid-Mediated Drug Testing and Clonality Analysis in Peritoneal Surface Disease of Intestinal Origin
$478,598Konstantinos Votanopoulos · Wake Forest University Health Sciences · R01 · FY2024 · CA
Targeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to Immunotherapy
$478,551Roberta Zappasodi · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
Targeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to Immunotherapy
$478,551Roberta Zappasodi · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma
$478,486Keiran Smalley · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · CA
Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple Myeloma
$478,447Suzanne Lentzsch · Columbia University Health Sciences · R01 · FY2025 · CA
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
$478,396Jerry D Glickson · University Of Pennsylvania · R01 · FY2020 · CA
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision Therapy
$478,383J. Silvio Gutkind · University Of California, San Diego · R01 · FY2018 · DE
Project 4: Therapeutic Targeting of Replication Stress Vulnerabilities in Small Cell Lung Cancer
$478,337Lauren Averett Byers · Ut Southwestern Medical Center · P50 · FY2024 · CA
OST Inhibition in NSCLC
$478,219Joseph N Contessa · Yale University · R01 · FY2022 · CA
OST Inhibition in NSCLC
$478,219Joseph N Contessa · Yale University · R01 · FY2023 · CA
AHR-mediated immunosuppression in glioblastoma
$478,176Francisco J. Quintana · Brigham And Women'S Hospital · R01 · FY2021 · ES
Dissecting the NRG4 hormonal checkpoint in metabolic liver disease
$478,123Jiandie D Lin · University Of Michigan At Ann Arbor · R01 · FY2023 · DK
Dissecting the NRG4 hormonal checkpoint in metabolic liver disease
$478,123Jiandie D Lin · University Of Michigan At Ann Arbor · R01 · FY2022 · DK
Signal and Transcription Factor Network interactions in Head and Neck Cancer
$478,080Carter Van Waes · National Institute On Deafness And Other Communication Disorders · ZIA · FY2019 · DC
Mechanisms of cell death in cutaneous melanoma
$477,822Andrew E Aplin · Thomas Jefferson University · R01 · FY2025 · CA
Mechanisms of cell death in cutaneous melanoma
$477,822Andrew E Aplin · Thomas Jefferson University · R01 · FY2021 · CA
Project 2: Redirecting pre-existing anti-viral immunity to HNSCCs with APECs
$477,775Thorsten Roman Mempel · Yale University · P01 · FY2023 · CA
Novel immune suppressive activities of Fas/CD95 in triple negative breast cancer
$477,698Marcus E Peter · Northwestern University At Chicago · R01 · FY2025 · CA
The Adenosinergic Pathway in Tumor-derived Exosomes
$477,653Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA
Novel therapeutic approaches with CDK4/6 inhibitors for melanoma treatment
$477,643Piotr Sicinski · Dana-Farber Cancer Inst · R01 · FY2020 · CA
Novel therapeutic approaches with CDK4/6 inhibitors for melanoma treatment
$477,643Piotr Sicinski · Dana-Farber Cancer Inst · R01 · FY2019 · CA